PURPOSE: This study was designed to provide preliminary data regarding the safety and efficacy of high-dose humanized anti-IL-2 receptor (daclizumab) therapy for the treatment of active intermediate, posterior or panuveitis. METHODS: Five patients were recruited into this non-randomized, prospective pilot study of high-dose intravenous induction daclizumab therapy given at doses of 8mg/kg at day 0 and 4mg/kg at day 14. Patients who did not meet a safety endpoint at the 3-week follow-up evaluation were given the option of continuing therapy with subcutaneous daclizumab at 2mg/kg every 4 weeks for 52 weeks. The primary outcome assessed was a two-step decrease in vitreous haze at day 21. Secondary outcomes evaluated included best-corrected visual acuity, retinal thickness as measured by optical coherence tomography, retinal vascular leakage assessed by fluorescein angiography, anterior chamber and vitreous cellular inflammation. RESULTS: Four male patients and one female patient were enrolled. Diagnoses included birdshot retinochoroidopathy (two patients), Vogt-Koyanagi-Harada's disease, bilateral idiopathic panuveitis and bilateral idiopathic intermediate uveitis. By the 4th week, four of five patients demonstrated a two-step decrease in vitreous haze. The other participant did not meet this criterion until week 20, but all five patients maintained stability in vitreous haze grade throughout their follow-up periods. At enrollment, mean visual acuity (10 eyes in 5 patients) was 69.2 ETDRS letters and following treatment was 78.2 letters (p<0.12). Anterior chamber cell, vitreous cell, and vitreous haze also improved in the majority of eyes. Adverse events were generally mild except for one episode of left-lower lobe pneumonia requiring hospitalization and treatment. CONCLUSION: This is the first demonstration that high-dose daclizumab can reduce inflammation in active uveitis. Daclizumab was well tolerated but there may be a potential increased risk of infection associated with immunosuppression. All five patients demonstrated a decrease in vitreous haze and measures of intraocular inflammation at final follow-up. The results of this small, non-randomized pilot study support the consideration of high-dose daclizumab therapy in cases of active posterior uveitis.
PURPOSE: This study was designed to provide preliminary data regarding the safety and efficacy of high-dose humanized anti-IL-2 receptor (daclizumab) therapy for the treatment of active intermediate, posterior or panuveitis. METHODS: Five patients were recruited into this non-randomized, prospective pilot study of high-dose intravenous induction daclizumab therapy given at doses of 8mg/kg at day 0 and 4mg/kg at day 14. Patients who did not meet a safety endpoint at the 3-week follow-up evaluation were given the option of continuing therapy with subcutaneous daclizumab at 2mg/kg every 4 weeks for 52 weeks. The primary outcome assessed was a two-step decrease in vitreous haze at day 21. Secondary outcomes evaluated included best-corrected visual acuity, retinal thickness as measured by optical coherence tomography, retinal vascular leakage assessed by fluorescein angiography, anterior chamber and vitreous cellular inflammation. RESULTS: Four male patients and one female patient were enrolled. Diagnoses included birdshot retinochoroidopathy (two patients), Vogt-Koyanagi-Harada's disease, bilateral idiopathic panuveitis and bilateral idiopathic intermediate uveitis. By the 4th week, four of five patients demonstrated a two-step decrease in vitreous haze. The other participant did not meet this criterion until week 20, but all five patients maintained stability in vitreous haze grade throughout their follow-up periods. At enrollment, mean visual acuity (10 eyes in 5 patients) was 69.2 ETDRS letters and following treatment was 78.2 letters (p<0.12). Anterior chamber cell, vitreous cell, and vitreous haze also improved in the majority of eyes. Adverse events were generally mild except for one episode of left-lower lobe pneumonia requiring hospitalization and treatment. CONCLUSION: This is the first demonstration that high-dose daclizumab can reduce inflammation in active uveitis. Daclizumab was well tolerated but there may be a potential increased risk of infection associated with immunosuppression. All five patients demonstrated a decrease in vitreous haze and measures of intraocular inflammation at final follow-up. The results of this small, non-randomized pilot study support the consideration of high-dose daclizumab therapy in cases of active posterior uveitis.
Authors: Bibiana Bielekova; Marta Catalfamo; Susan Reichert-Scrivner; Amy Packer; Magdalena Cerna; Thomas A Waldmann; Henry McFarland; Pierre A Henkart; Roland Martin Journal: Proc Natl Acad Sci U S A Date: 2006-04-03 Impact factor: 11.205
Authors: Joan Figueras; Martin Prieto; Angel Bernardos; Antoni Rimola; Francisco Suárez; Jorge Ortiz de Urbina; Valentín Cuervas-Mons; Manuel de la Mata Journal: Transpl Int Date: 2006-08 Impact factor: 3.782
Authors: Eric M Yoshida; Paul J Marotta; Paul D Greig; Norman M Kneteman; Denis Marleau; Marcelo Cantarovich; Kevork M Peltekian; Leslie B Lilly; Charles H Scudamore; Vincent G Bain; William J Wall; Andre Roy; Robert F Balshaw; Jeffrey S T Barkun Journal: Liver Transpl Date: 2005-09 Impact factor: 5.799
Authors: R B Nussenblatt; E Fortin; R Schiffman; L Rizzo; J Smith; P Van Veldhuisen; P Sran; A Yaffe; C K Goldman; T A Waldmann; S M Whitcup Journal: Proc Natl Acad Sci U S A Date: 1999-06-22 Impact factor: 11.205
Authors: Robert B Nussenblatt; Jan S Peterson; C Stephen Foster; Narsing A Rao; Robert F See; Eric Letko; Ronald R Buggage Journal: Ophthalmology Date: 2005-05 Impact factor: 12.079
Authors: F Vincenti; R Kirkman; S Light; G Bumgardner; M Pescovitz; P Halloran; J Neylan; A Wilkinson; H Ekberg; R Gaston; L Backman; J Burdick Journal: N Engl J Med Date: 1998-01-15 Impact factor: 91.245
Authors: John C Mullen; Antigone Oreopoulos; Dale C Lien; Michael J Bentley; Dennis L Modry; Ken Stewart; Timothy L Winton; Kathy Jackson; Karen Doucette; Jutta Preiksaitis; Phil F Halloran Journal: J Heart Lung Transplant Date: 2007-03-26 Impact factor: 10.247
Authors: Keith Wroblewski; H Nida Sen; Steven Yeh; Lisa Faia; Zhuging Li; Pushpa Sran; Sapna Gangaputra; Susan Vitale; Patti Sherry; Robert Nussenblatt Journal: Can J Ophthalmol Date: 2011-07-07 Impact factor: 1.882
Authors: Jennifer L Rogers; Donald S Serafin; Roman G Timoshchenko; Teresa K Tarrant Journal: Curr Allergy Asthma Rep Date: 2012-12 Impact factor: 4.806
Authors: Elaine M Sloand; Matthew J Olnes; Barbara Weinstein; Colin Wu; Jaroslaw Maciejewski; Phillip Scheinberg; Neal S Young Journal: Haematologica Date: 2010-03 Impact factor: 9.941
Authors: H Nida Sen; Grace Levy-Clarke; Lisa J Faia; Zhuqing Li; Steven Yeh; Karyl S Barron; John G Ryan; Keri Hammel; Robert B Nussenblatt Journal: Am J Ophthalmol Date: 2009-08-06 Impact factor: 5.258